A SspI PCR-RFLP detecting a silent allele at the goat CSN2 locus

The comparison between the cDNA sequence obtained and the published sequences of the goat CSN2 alleles showed a new single nucleotide polymorphism (SNP) (transition C-T) at the 180th nucleotide of the ninth exon. This mutation, which took place at 124 nt from the polyadenylation site, identifies a silent allele at the CSN2 locus named CSN2 A1. Since the 9th exon C-T transition creates a SspI endonuclease restriction site, the SspI digestion of a PCR product of 360 bp spanning the 9th exon and flanking regions, would allow carriers for the presence of thymine to be identified. The allelic frequency of the CSN2 A1 allele, determined in 170 goats belonging to an undefined genetic type reared in the province of Naples (Italy), was 0.23 It has been observed that the sequences in the 3’ untranslated regions (UTR), proximal to the polyadenylation site, can affect the mechanism of mRNA deadenylation and degradation. Therefore, it is reasonable to hypothesize that the C-T transition might, directly or indirectly, influence the stability of the mRNA and, consequently, the amount of protein produced

Vaccinia virus binds to the scavenger receptor MARCO on the surface of keratinocytes.

Patients with altered skin immunity, such as individuals with atopic dermatitis (AD), can have a life-threatening disruption of the epidermis known as eczema vaccinatum after vaccinia virus (VV) infection of the skin. Here, we sought to better understand the mechanism(s) by which VV associates with keratinocytes. The class A scavenger receptor known as MARCO (macrophage receptor with collagenous structure) is expressed on human and mouse keratinocytes and found to be abundantly expressed in the skin of patients with AD. VV bound directly to MARCO, and overexpression of MARCO increased susceptibility to VV infection. Furthermore, ligands with affinity for MARCO, or excess soluble MARCO, competitively inhibited VV infection. These findings indicate that MARCO promotes VV infection and highlights potential new therapeutic strategies for prevention of VV infection in the skin

Recovery of erection after pelvic urologic surgery: our experience

n/

Aggregation and remuneration in Demand-Response with a blockchain-based framework

This paper describes the possibility to use the blockchain technology for load and generation aggregation in a new distributed Demand Response (DR) service and customers remuneration system. The blockchain technology and the use of smart contracts for DR allow the creation of a distributed system in which customers can communicate directly, in a transparent, secure and traceable way, with the grid operator to provide their flexibility. In this paper, the DR problem formulation takes into account several aspects, which are periodically executed. First, the blockchain records customers’ energy consumption or production, then, the smart contract starts calculating the baseline and the potential support provided by each customer to fulfil the requested load adaptation. Customers’ availability for generation and load profile modulation is also taken into account, as well as their privacy and an updated definition of the roles of grid and market operators in a new Demand-Response scenario supported by the blockchain technology. The blockchain used is Hyperledger Fabric, since it turned to be flexible for smart contracts implementation while supporting multi-tenancy. Results show the possibility to successfully apply the blockchain technology to this particular topic, even considering privacy-preserving issues

The machine protection system for the ELI-NP gamma beam system

The new Gamma Beam System (GBS) of the ELI-NPproject [1], currently under installation in Magurele (RO)by INFN, as part of EuroGammas consortium, can providegamma rays that open new possibilities for nuclear photonicsand nuclear physics.ELI-NP gamma rays are produced by Compton back-scattering to get monochromaticity (0,1% bandwidth), highflux (1013photons), tunable direction and energy up to19.5 MeV. Such gamma beam is obtained when a high-intensity laser collides a high-brightness electron beam withenergies up to740 MeV, a repetition rate of100 Hz, withtrains of 32 bunches within the same RF bucket.An advanced Machine Protection System (MPS) has beendeveloped, in order to ensure proper operation for this chal-lenging facility. The MPS operates on different layers of thecontrol system and is interfaced with all its sub-systems. Forinstance, it comprises different kind of beam loss monitors(based on Cherenkov optical fiber), hall probes, fast currenttransformer together with BPMs, and an embedded systembased on FPGA with distributed I/O over EtherCAT, to mon-itor vacuum and RF systems [2], which require fast responseto be interlocked within one RF pulse

5-En-androstene-3 beta,17 beta-diol inhibits the growth of MCF-7 breast cancer cells when oestrogen receptors are blocked by oestradiol.

Adrenal androgens show a dual and apparently opposite effect on the growth of oestrogen-responsive breast cancer: they stimulate growth on their own, but counteract the growth-stimulatory effect of oestrogens. Focusing on the inhibitory action we have studied the effects of 5-en-androstene-3 beta,17 beta-diol (ADIOL) on the growth of oestrogen-responsive MCF-7 breast cancer cells in the presence of oestrogens (oestradiol and diethylstilboestrol), antiestrogens (tamoxifen) and antiandrogens (hydroxyflutamide). The inhibition of oestrogen-stimulated growth, attained with nanomolar concentrations of ADIOL, was not modified by increasing concentrations of diethylstilboestrol up to 100 nM. This inhibition was counteracted by antiandrogens, which were unable to block the ADIOL stimulatory effect in steroid-free medium. On the other hand, in the presence of tamoxifen ADIOL showed an additive antiproliferative activity also in steroid-free medium, rather than the usual stimulatory effect. These results suggest that ADIOL stimulates breast cancer cell growth via oestrogen receptors, but inhibits oestrogen-stimulated growth via androgen receptors

Role of glucose-6-phosphate dehydrogenase inhibition in the antiproliferative effects of dehydroepiandrosterone on human breast cancer cells.

Epidemiological and experimental studies suggest that dehydroepiandrosterone (DHEA) exerts a protective effect against breast cancer. It has been proposed that the non-competitive inhibition of glucose-6-phosphate dehydrogenase (G6PD) contributes to DHEA antitumor action. We evaluated the effects of DHEA on G6PD activity and on the in vitro proliferation of two human breast cancer cell lines, MCF-7 (steroid receptor positive) and MDA-MB-231 (steroid receptor negative), in a serum-free assay. DHEA inhibition of G6PD was only found to occur at concentrations above 10 microM; at these high concentrations, the growth curve was parallel to the enzyme inhibition curve in both cell lines. In contrast, at concentrations in the in vivo breast tissue concentration range, neither cell growth nor enzyme activity was inhibited. The results failed to confirm DHEA's putative anti-tumor action on breast cancer through G6PD inhibition, as the enzyme blockade only becomes apparent at pharmacological concentrations of the steroid